Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth.

C-REV HSV cetuximab human colorectal cancer oncolytic herpes virus HF10

Journal

Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776

Informations de publication

Date de publication:
28 Jun 2019
Historique:
received: 09 10 2018
accepted: 24 04 2019
entrez: 14 6 2019
pubmed: 14 6 2019
medline: 14 6 2019
Statut: epublish

Résumé

The naturally occurring oncolytic herpes simplex virus canerpaturev (C-REV), formerly HF10, proved its therapeutic efficacy and safety in multiple clinical trials against melanoma, pancreatic, breast, and head and neck cancers. Meanwhile, patients with colorectal cancer, which has increased in prevalence in recent decades, continue to have poor prognosis and morbidity. Combination therapy has better response rates than monotherapy. Hence, we investigated the antitumor efficacy of cetuximab, a widely used anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and C-REV, either alone or in combination,

Identifiants

pubmed: 31193737
doi: 10.1016/j.omto.2019.04.004
pii: S2372-7705(19)30052-X
pmc: PMC6539424
doi:

Types de publication

Journal Article

Langues

eng

Pagination

107-115

Références

Cancer Res. 2000 Apr 15;60(8):2190-6
pubmed: 10786683
Clin Cancer Res. 2000 May;6(5):1936-48
pubmed: 10815919
Clin Cancer Res. 2000 Sep;6(9):3739-47
pubmed: 10999768
J Med Entomol. 2000 Nov;37(6):815-9
pubmed: 11126535
J Clin Oncol. 2001 Jan 15;19(2):289-98
pubmed: 11208818
Cancer Res. 2001 Jan 15;61(2):517-25
pubmed: 11212244
J Virol Methods. 2001 Aug;96(2):107-26
pubmed: 11445142
Am J Pathol. 2001 Sep;159(3):1021-9
pubmed: 11549594
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8944-9
pubmed: 12060721
Cancer Res. 2004 Apr 1;64(7):2561-7
pubmed: 15059912
Cancer Res. 1992 Sep 15;52(18):5110-4
pubmed: 1516068
Nat Rev Cancer. 2004 Oct;4(10):806-13
pubmed: 15510161
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5838-43
pubmed: 15824310
Int J Cancer. 2005 Dec 20;117(6):883-8
pubmed: 16152621
Urology. 2005 Nov;66(5):1116-21
pubmed: 16286150
Nat Rev Cancer. 2005 Dec;5(12):965-76
pubmed: 16294217
J Virol. 1991 Aug;65(8):4520-4
pubmed: 1649347
Ann Surg Oncol. 2006 Aug;13(8):1078-84
pubmed: 16865590
Acta Otolaryngol. 2006 Oct;126(10):1115-7
pubmed: 16923721
Cancer Res. 2007 Jan 15;67(2):440-4
pubmed: 17234749
Nat Clin Pract Oncol. 2007 Feb;4(2):101-17
pubmed: 17259931
Curr Cancer Drug Targets. 2007 Mar;7(2):169-74
pubmed: 17346108
Ann Oncol. 2007 Jun;18 Suppl 6:vi35-41
pubmed: 17591829
Mol Ther. 2008 Aug;16(8):1382-91
pubmed: 18545226
Arch Virol. 2009;154(2):219-26
pubmed: 19115032
Mol Ther. 2010 Feb;18(2):285-94
pubmed: 19844198
J Exp Med. 2010 Jan 18;207(1):101-15
pubmed: 20026662
Eur J Cancer. 2010 Jun;46(9):1703-11
pubmed: 20399639
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):127-34
pubmed: 20399700
Cancer Gene Ther. 2011 Mar;18(3):167-75
pubmed: 21102422
Cancer Gene Ther. 2012 Apr;19(4):229-37
pubmed: 22193629
Mol Ther. 2013 May;21(5):1014-23
pubmed: 23481323
Jpn J Clin Oncol. 2013 May;43(5):492-507
pubmed: 23493744
Ann Surg Oncol. 2014 Feb;21(2):691-8
pubmed: 24170435
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
Nat Rev Microbiol. 2014 Jan;12(1):23-34
pubmed: 24292552
MBio. 2014 Jan 14;5(1):e00958-13
pubmed: 24425731
Digestion. 2014;89(1):18-23
pubmed: 24458108
Oncol Rep. 2014 May;31(5):2115-22
pubmed: 24626880
Int J Cancer. 2015 Apr 1;136(7):1718-30
pubmed: 25156870
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Hepatogastroenterology. 2014 May;61(131):599-605
pubmed: 26176043
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Drugs. 2016 Jan;76(1):147-54
pubmed: 26620366
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Oncolytic Virother. 2017 Mar 13;6:31-38
pubmed: 28331843
BMC Cancer. 2018 May 25;18(1):596
pubmed: 29801474
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
pubmed: 7612182
Cancer Res. 1996 Sep 15;56(18):4264-6
pubmed: 8797602
Ann Surg. 1996 Sep;224(3):323-9; discussion 329-30
pubmed: 8813260
Nature. 1998 Jan 1;391(6662):24-5
pubmed: 9422503

Auteurs

Zhiwen Wu (Z)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.
Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Toru Ichinose (T)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.
Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Yoshinori Naoe (Y)

Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Shigeru Matsumura (S)

Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Itzel Bustos Villalobos (IB)

Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Ibrahim Ragab Eissa (IR)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.
Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Suguru Yamada (S)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Noriyuki Miyajima (N)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Daishi Morimoto (D)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Nobuaki Mukoyama (N)

Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Yoko Nishikawa (Y)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Yusuke Koide (Y)

Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Yasuhiro Kodera (Y)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Maki Tanaka (M)

Takara Bio Inc., 7-4-38, Nojihigashi, Kusatsu 525-0058, Shiga, Japan.

Hideki Kasuya (H)

Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.
Cancer Immune Therapy Research Center, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Aichi, Japan.

Classifications MeSH